Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism

Xenobiotica

Volumn 43, Issue 7, 2013, Pages 641-649

  Chitnis, Shripad D ^a   Ogasawara, Ken ^a   Schniedewind, Björn ^b   Gohh, Reginald Y ^c   Christians, Uwe ^b   Akhlaghi, Fatemeh ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Clearance; CYP3A4*1B; CYP3A5*1; Diabetes; Pharmacokinetics; Tacrolimus metabolites

Indexed keywords

13 O DESMETHYL TACROLIMUS; 15 O DESMETHYL TACROLIMUS; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; CYTOCHROME P-450 CYP3A; DIABETES MELLITUS; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 84878878202     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.752118     Document Type: Article

References (39)

1. Akhlaghi F, Dostalek M, Falck P, et al. (2012). The concentration of cyclosporine metabolites is significantly lower in kidney transplant recipients with diabetes mellitus. Ther Drug Monit 34:38-45.
2. Akhlaghi F, Patel CG, Zuniga XP, et al. (2006). Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. Ther Drug Monit 28:95-101. (Pubitemid 44391701)
3. Ansermot N, Fathi M, Veuthey JL, et al. (2008). Quantification of cyclosporine and tacrolimus in whole blood. Comparison of liquid chromatography-electrospray mass spectrometry with the enzyme multiplied immunoassay technique. Clin Biochem 41:910-13.
4. Carvalho TM, Cavalli Rde C, Cunha SP, et al. (2011). Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients. Eur J Clin Pharmacol 67:55-61.
5. Cheng PY, Morgan ET. (2001). Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2:165-83. (Pubitemid 32544553)
6. Christians U. (2005). Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol 1:641-54.
7. Christians U, Jacobsen W, Serkova N, et al. (2000). Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immuno-suppressants. J Chromatogr B Biomed Sci Appl 748:41-53.
8. Dai Y, Hebert MF, Isoherranen N, et al. (2006). Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836-47.
9. Dostalek M, Akhlaghi F, Puzanovova M. (2012a). Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet 51:481-99.
10. Dostalek M, Court MH, Hazarika S, et al. (2011b). Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos 39:448-55.
11. Dostalek M, Court MH, Yan B, et al. (2011a). Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol 163:937-47.
12. Dostalek M, Sam WJ, Paryani KR, et al. (2012b). Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. Clin Pharmacokinet 51:591-606.
13. Firdaous I, Verbeeck RK, Hassoun A, et al. (1997). Excretion of tacrolimus glucuronides in human bile. Eur J Drug Metab Pharmacokinet 22:217-21. (Pubitemid 27475111)
14. He P, Court MH, Greenblatt DJ, et al. (2005). Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77:373-87. (Pubitemid 40719266)
15. Hoffmeyer S, Burk O, von Richter O, et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-8. (Pubitemid 30183327)
16. Hustert E, Haberl M, Burk O, et al. (2001). The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-9. (Pubitemid 33151512)
17. Iwasaki K. (2007). Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 22:328-35.
18. Iwasaki K, Shiraga T, Nagase K, et al. (1993). Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab Dispos 21:971-7. (Pubitemid 23348331)
19. Johne A, Köpke K, Gerloff T, et al. (2002). Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72:584-94. (Pubitemid 36237730)
20. Kamdem LK, Streit F, Zanger UM, et al. (2005). Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 51:1374-81. (Pubitemid 41060869)
21. Karanam BV, Vincent SH, Newton DJ, et al. (1994). FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. Drug Metab Dispos 22:811-14. (Pubitemid 24307498)
22. Kerb R, Aynacioglu AS, Brockmoller J, et al. (2001). The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenom J 1:204-10.
23. Kuehl P, Zhang J, Lin Y, et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-91. (Pubitemid 32268418)
24. Kuo HT, Sampaio MS, Vincenti F, et al. (2010). Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 56:1127-39.
25. Lamba JK, Lin YS, Schuetz EG, et al. (2002). Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-94. (Pubitemid 35284253)
26. Lampen A, Christians U, Guengerich FP, et al. (1995). Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 23:1315-24. (Pubitemid 26007838)
27. Laverdiere I, Caron P, Harvey M, et al. (2011). In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacro-limus glucuronidation: predominant contribution of UGT1A4. Drug Metab Dispos 39:1127-30.
28. Mancinelli LM, Frassetto L, Floren LC, et al. (2001). The pharmaco-kinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 69:24-31. (Pubitemid 32108668)
29. Marques MP, Coelho EB, Dos Santos NA, et al. (2002). Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. Eur J Clin Pharmacol 58:607-14. (Pubitemid 35478187)
30. Mendonza AE, Zahir H, Gohh RY, et al. (2007). Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 29:391-8. (Pubitemid 47220454)
31. Moises EC, Duarte Lde B, Cavalli Rde C, et al. (2008). Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. Eur J Clin Pharmacol 64:1189-96.
32. Saeki T, Ueda K, Tanigawara Y, et al. (1993). Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268:6077-80. (Pubitemid 23099291)
33. Sattler M, Guengerich FP, Yun CH, et al. (1992). Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20:753-61.
34. Staatz CE, Goodman LK, Tett SE. (2010). Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 49:141-75.
35. Staatz CE, Tett SE. (2004). Clinical pharmacokinetics and pharmaco-dynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623-53. (Pubitemid 38981845)
36. van Duijnhoven E, Christiaans M, Schäfer A, et al. (1998). Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. Transplant Proc 30:1266-7. (Pubitemid 28309566)
37. Venkataramanan R, Swaminathan A, Prasad T, et al. (1995). Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29:404-30. (Pubitemid 26004179)
38. Wild S, Roglic G, Green A, et al. (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-53. (Pubitemid 38579764)
39. Zini R, Riant P, Barre J, Tillement JP. (1990). Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part I). Clin Pharmacokinet, 19:147-59. (Pubitemid 20211325)